BPC-157, a pentadecapeptide, is often researched for its cytoprotective and organo-protective properties, particularly within the gastrointestinal tract and in soft tissues like ligaments and tendons
Combination start only after stabilization on GLP-1 (2.4 mg or 5 mg)
Journal of the Science of Food and Agriculture
Tirzepatide, on the other hand, is a newer medication that also targets both GLP-1 and GIP receptors but has gained significant attention due to its impressive results in clinical trials and recent FDA approval for type 2 diabetes treatment
Its structure (thickness ranges from 20 to 6450 nm in different species) not only provides a charge-selective barrier but also serves to anchor mechanosensors such as the glypican-1 (GPC-1)/caveolin-1 (CAV-1) complex and buffers shear stress
While we mentioned a few BPC-157 oral formulations above, some researchers might be interested in BPC-157 capsules that only include BPC-157 with no other peptides